+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Women's Health Diagnostics Market Research Report by Application, by End User, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 4829897
  • Report
  • July 2021
  • Region: Global
  • 190 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Women’s Health Diagnostics Market will Grow to USD 56.99 Billion by 2026, at a CAGR of 8.91%

FEATURED COMPANIES

  • Abbott Laboratories
  • Biomérieux SA
  • Carestream Health, Inc.
  • DIALAB GmbH
  • Guided Therapeutics, Inc.
  • MedGyn Products, Inc.
  • MORE
The Global Women’s Health Diagnostics Market size was estimated at USD 34.14 Billion in 2020 and expected to reach USD 37.07 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 8.91% to reach USD 56.99 Billion by 2026.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Women’s Health Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Application, the Women’s Health Diagnostics Market was studied across Breast Cancer Testing, Cervical Cancer Testing, Infectious Disease Testing, Osteoporosis Testing, Ovarian Cancer Testing, Pregnancy and Fertility Testing, Prenatal Genetic Screening and Carrier Testing, Sexually Transmitted Disease Testing, and Ultrasound Tests. The Breast Cancer Testing is further studied across Biopsies, Blood Chemistries and Blood Cell Count Tests, Breast Cancer Tumor Marker Tests, and Mammography. The Cervical Cancer Testing is further studied across HPV Testing and PAP Smear. The Infectious Disease Testing is further studied across HEPAtitis Testing, MRSA Testing, Tuberculosis Testing, and Urinary Tract Infection Testing (Vaginal Ph & Vaginitis). The Osteoporosis Testing is further studied across Bone Densitometry and in Vitro Blood Tests. The Ovarian Cancer Testing is further studied across Diagnostic Imaging Tests and Ovarian Cancer Tumor Marker Tests. The Pregnancy and Fertility Testing is further studied across Fertility Monitors, Lab-Based Testing, and Pregnancy Testing and Ovulation Prediction Kits. The Prenatal Genetic Screening and Carrier Testing is further studied across Cystic Fibrosis, Down Syndrome and Edwards Syndrome, and Torch Infections. The Sexually Transmitted Disease Testing is further studied across Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing and HIV Testing. The Ultrasound Tests is further studied across Breast Imaging and OB/GYN Imaging.
  • Based on Type, the Women’s Health Diagnostics Market was studied across Point-of-care and Self Check.
  • Based on End User, the Women’s Health Diagnostics Market was studied across Diagnostic and Imaging Centers, Home Care, and Hospitals and Clinics.
  • Based on Region, the Women’s Health Diagnostics Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Women’s Health Diagnostics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Women’s Health Diagnostics Market, including Abbott Laboratories, AccuBioTech Co., Ltd., Alere Inc., Becton, Dickinson and Company, Biomérieux SA, bioMérieux SA, Cardinal Health, Inc., Carestream Health, Inc., Chembio Diagnostic Systems, Inc., Cook Medical, Inc., Danaher Corporation, DIALAB GmbH, EKF Diagnostics Holdings plc, F. Hoffmann-La Roche Ltd., FUJIFILM Holdings Corporation, GE Healthcare, Guided Therapeutics, Inc., Hologic, Inc., Koninklijke Philips N.V., MedGyn Products, Inc., NeuroLogica Corporation, Nova Biomedical, Osteometer MediTech, Inc., Perkinelmer Inc., Quest Diagnostics Incorporated, Siemens AG, SuperSonic Imagine, and WerfenLife, S.A..

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Women’s Health Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Women’s Health Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Women’s Health Diagnostics Market?
4. What is the competitive strategic window for opportunities in the Global Women’s Health Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global Women’s Health Diagnostics Market?
6. What is the market share of the leading vendors in the Global Women’s Health Diagnostics Market?
7. What modes and strategic moves are considered suitable for entering the Global Women’s Health Diagnostics Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Biomérieux SA
  • Carestream Health, Inc.
  • DIALAB GmbH
  • Guided Therapeutics, Inc.
  • MedGyn Products, Inc.
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Application Outlook
3.4. Type Outlook
3.5. End User Outlook
3.6. Region Outlook
3.7. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing instances of chronic and life style- related disorders in women
5.1.1.2. Awareness about fertility testing in women coupled with initiatives taken by health organizations and government
5.1.1.3. Adoption of point-of-care and rapid diagnostic tests
5.1.1.4. Availability of imaging and private diagnostic centres
5.1.1.5. PPP to develop the modern infrastructure of diagnostic imaging centres
5.1.2. Restraints
5.1.2.1. Limited technically skilled lab assistants
5.1.3. Opportunities
5.1.3.1. Improved and technically advanced healthcare infrastructure in emerging economies
5.1.3.2. Regulatory approvals for immunoassay diagnostics techniques
5.1.3.3. Growing focus on microfluidics and nanotechnology-based POC devices for diagnostic
5.1.3.4. Clinical trial assessment for the diagnosis of breast cancer
5.1.4. Challenges
5.1.4.1. High cost associated with procedures and diagnostic imaging systems
5.1.4.2. Stringent regulatory guidelines
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Women’s Health Diagnostics Market, by Application
6.1. Introduction
6.2. Breast Cancer Testing
6.2.1. Biopsies
6.2.2. Blood Chemistries and Blood Cell Count Tests
6.2.3. Breast Cancer Tumor Marker Tests
6.2.4. Mammography
6.3. Cervical Cancer Testing
6.3.1. HPV Testing
6.3.2. PAP Smear
6.4. Infectious Disease Testing
6.4.1. HEPAtitis Testing
6.4.2. MRSA Testing
6.4.3. Tuberculosis Testing
6.4.4. Urinary Tract Infection Testing (Vaginal Ph & Vaginitis)
6.5. Osteoporosis Testing
6.5.1. Bone Densitometry
6.5.2. in Vitro Blood Tests
6.6. Ovarian Cancer Testing
6.6.1. Diagnostic Imaging Tests
6.6.2. Ovarian Cancer Tumor Marker Tests
6.7. Pregnancy and Fertility Testing
6.7.1. Fertility Monitors
6.7.2. Lab-Based Testing
6.7.3. Pregnancy Testing and Ovulation Prediction Kits
6.8. Prenatal Genetic Screening and Carrier Testing
6.8.1. Cystic Fibrosis
6.8.2. Down Syndrome and Edwards Syndrome
6.8.3. Torch Infections
6.9. Sexually Transmitted Disease Testing
6.9.1. Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing
6.9.2. HIV Testing
6.10. Ultrasound Tests
6.10.1. Breast Imaging
6.10.2. OB/GYN Imaging

7. Women’s Health Diagnostics Market, by Type
7.1. Introduction
7.2. Point-of-care
7.3. Self Check

8. Women’s Health Diagnostics Market, by End User
8.1. Introduction
8.2. Diagnostic and Imaging Centers
8.3. Home Care
8.4. Hospitals and Clinics

9. Americas Women’s Health Diagnostics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Women’s Health Diagnostics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Thailand

11. Europe, Middle East & Africa Women’s Health Diagnostics Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Abbott Laboratories
13.2. AccuBioTech Co., Ltd.
13.3. Alere Inc.
13.4. Becton, Dickinson and Company
13.5. Biomérieux SA
13.6. bioMérieux SA
13.7. Cardinal Health, Inc.
13.8. Carestream Health, Inc.
13.9. Chembio Diagnostic Systems, Inc.
13.10. Cook Medical, Inc.
13.11. Danaher Corporation
13.12. DIALAB GmbH
13.13. EKF Diagnostics Holdings plc
13.14. F. Hoffmann-La Roche Ltd.
13.15. FUJIFILM Holdings Corporation
13.16. GE Healthcare
13.17. Guided Therapeutics, Inc.
13.18. Hologic, Inc.
13.19. Koninklijke Philips N.V.
13.20. MedGyn Products, Inc.
13.21. NeuroLogica Corporation
13.22. Nova Biomedical
13.23. Osteometer MediTech, Inc.
13.24. Perkinelmer Inc.
13.25. Quest Diagnostics Incorporated
13.26. Siemens AG
13.27. SuperSonic Imagine
13.28. WerfenLife, S.A.

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2020 VS 2026 (USD BILLION)
FIGURE 2. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2020 (USD BILLION)
FIGURE 3. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2020 (USD BILLION)
FIGURE 4. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2020 (USD BILLION)
FIGURE 5. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY REGION, 2020 (USD BILLION)
FIGURE 6. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 7. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET: MARKET DYNAMICS
FIGURE 8. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 9. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2020 VS 2026 (%)
FIGURE 10. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2020 VS 2026 (USD BILLION)
FIGURE 11. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2026
FIGURE 12. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, 2018-2026 (USD BILLION)
FIGURE 13. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 14. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY BIOPSIES, 2018-2026 (USD BILLION)
FIGURE 15. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY BIOPSIES, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 16. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRIES AND BLOOD CELL COUNT TESTS, 2018-2026 (USD BILLION)
FIGURE 17. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRIES AND BLOOD CELL COUNT TESTS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 18. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TUMOR MARKER TESTS, 2018-2026 (USD BILLION)
FIGURE 19. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TUMOR MARKER TESTS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 20. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 21. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 22. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, 2018-2026 (USD BILLION)
FIGURE 23. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 24. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY HPV TESTING, 2018-2026 (USD BILLION)
FIGURE 25. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY HPV TESTING, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 26. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY PAP SMEAR, 2018-2026 (USD BILLION)
FIGURE 27. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY PAP SMEAR, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 28. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2026 (USD BILLION)
FIGURE 29. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 30. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY HEPATITIS TESTING, 2018-2026 (USD BILLION)
FIGURE 31. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY HEPATITIS TESTING, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 32. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY MRSA TESTING, 2018-2026 (USD BILLION)
FIGURE 33. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY MRSA TESTING, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 34. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY TUBERCULOSIS TESTING, 2018-2026 (USD BILLION)
FIGURE 35. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY TUBERCULOSIS TESTING, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 36. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY URINARY TRACT INFECTION TESTING (VAGINAL PH & VAGINITIS), 2018-2026 (USD BILLION)
FIGURE 37. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY URINARY TRACT INFECTION TESTING (VAGINAL PH & VAGINITIS), BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 38. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, 2018-2026 (USD BILLION)
FIGURE 39. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 40. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY BONE DENSITOMETRY, 2018-2026 (USD BILLION)
FIGURE 41. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY BONE DENSITOMETRY, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 42. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY IN VITRO BLOOD TESTS, 2018-2026 (USD BILLION)
FIGURE 43. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY IN VITRO BLOOD TESTS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 44. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, 2018-2026 (USD BILLION)
FIGURE 45. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 46. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING TESTS, 2018-2026 (USD BILLION)
FIGURE 47. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING TESTS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 48. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TUMOR MARKER TESTS, 2018-2026 (USD BILLION)
FIGURE 49. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TUMOR MARKER TESTS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 50. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY AND FERTILITY TESTING, 2018-2026 (USD BILLION)
FIGURE 51. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY AND FERTILITY TESTING, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 52. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY FERTILITY MONITORS, 2018-2026 (USD BILLION)
FIGURE 53. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY FERTILITY MONITORS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 54. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY LAB-BASED TESTING, 2018-2026 (USD BILLION)
FIGURE 55. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY LAB-BASED TESTING, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 56. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY TESTING AND OVULATION PREDICTION KITS, 2018-2026 (USD BILLION)
FIGURE 57. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY TESTING AND OVULATION PREDICTION KITS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 58. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING AND CARRIER TESTING, 2018-2026 (USD BILLION)
FIGURE 59. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING AND CARRIER TESTING, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 60. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY CYSTIC FIBROSIS, 2018-2026 (USD BILLION)
FIGURE 61. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 62. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY DOWN SYNDROME AND EDWARDS SYNDROME, 2018-2026 (USD BILLION)
FIGURE 63. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY DOWN SYNDROME AND EDWARDS SYNDROME, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 64. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY TORCH INFECTIONS, 2018-2026 (USD BILLION)
FIGURE 65. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY TORCH INFECTIONS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 66. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, 2018-2026 (USD BILLION)
FIGURE 67. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 68. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TESTING, 2018-2026 (USD BILLION)
FIGURE 69. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TESTING, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 70. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY HIV TESTING, 2018-2026 (USD BILLION)
FIGURE 71. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY HIV TESTING, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 72. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, 2018-2026 (USD BILLION)
FIGURE 73. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 74. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST IMAGING, 2018-2026 (USD BILLION)
FIGURE 75. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST IMAGING, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 76. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY OB/GYN IMAGING, 2018-2026 (USD BILLION)
FIGURE 77. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY OB/GYN IMAGING, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 78. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2020 VS 2026 (%)
FIGURE 79. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2020 VS 2026 (USD BILLION)
FIGURE 80. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2026
FIGURE 81. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE, 2018-2026 (USD BILLION)
FIGURE 82. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 83. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY SELF CHECK, 2018-2026 (USD BILLION)
FIGURE 84. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY SELF CHECK, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 85. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2020 VS 2026 (%)
FIGURE 86. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2020 VS 2026 (USD BILLION)
FIGURE 87. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2026
FIGURE 88. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC AND IMAGING CENTERS, 2018-2026 (USD BILLION)
FIGURE 89. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC AND IMAGING CENTERS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 90. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY HOME CARE, 2018-2026 (USD BILLION)
FIGURE 91. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 92. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2026 (USD BILLION)
FIGURE 93. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 94. AMERICAS WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 95. ARGENTINA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 96. BRAZIL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 97. CANADA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 98. MEXICO WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 99. UNITED STATES WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 100. ASIA-PACIFIC WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 101. AUSTRALIA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 102. CHINA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 103. INDIA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 104. INDONESIA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 105. JAPAN WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 106. MALAYSIA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 107. PHILIPPINES WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 108. SINGAPORE WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 109. SOUTH KOREA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 110. THAILAND WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 111. EUROPE, MIDDLE EAST & AFRICA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 112. FRANCE WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 113. GERMANY WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 114. ITALY WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 115. NETHERLANDS WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 116. QATAR WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 117. RUSSIA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 118. SAUDI ARABIA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 119. SOUTH AFRICA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 120. SPAIN WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 121. UNITED ARAB EMIRATES WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 122. UNITED KINGDOM WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 123. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX
FIGURE 124. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 125. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET, BY TYPE

List of Tables
TABLE 1. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 4. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 5. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, BY REGION, 2018-2026 (USD BILLION)
TABLE 6. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY BIOPSIES, BY REGION, 2018-2026 (USD BILLION)
TABLE 7. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRIES AND BLOOD CELL COUNT TESTS, BY REGION, 2018-2026 (USD BILLION)
TABLE 8. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TUMOR MARKER TESTS, BY REGION, 2018-2026 (USD BILLION)
TABLE 9. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2018-2026 (USD BILLION)
TABLE 10. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, BY REGION, 2018-2026 (USD BILLION)
TABLE 11. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY HPV TESTING, BY REGION, 2018-2026 (USD BILLION)
TABLE 12. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY PAP SMEAR, BY REGION, 2018-2026 (USD BILLION)
TABLE 13. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2018-2026 (USD BILLION)
TABLE 14. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY HEPATITIS TESTING, BY REGION, 2018-2026 (USD BILLION)
TABLE 15. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY MRSA TESTING, BY REGION, 2018-2026 (USD BILLION)
TABLE 16. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY TUBERCULOSIS TESTING, BY REGION, 2018-2026 (USD BILLION)
TABLE 17. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY URINARY TRACT INFECTION TESTING (VAGINAL PH & VAGINITIS), BY REGION, 2018-2026 (USD BILLION)
TABLE 18. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, BY REGION, 2018-2026 (USD BILLION)
TABLE 19. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY BONE DENSITOMETRY, BY REGION, 2018-2026 (USD BILLION)
TABLE 20. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY IN VITRO BLOOD TESTS, BY REGION, 2018-2026 (USD BILLION)
TABLE 21. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, BY REGION, 2018-2026 (USD BILLION)
TABLE 22. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING TESTS, BY REGION, 2018-2026 (USD BILLION)
TABLE 23. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TUMOR MARKER TESTS, BY REGION, 2018-2026 (USD BILLION)
TABLE 24. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY AND FERTILITY TESTING, BY REGION, 2018-2026 (USD BILLION)
TABLE 25. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY FERTILITY MONITORS, BY REGION, 2018-2026 (USD BILLION)
TABLE 26. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY LAB-BASED TESTING, BY REGION, 2018-2026 (USD BILLION)
TABLE 27. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY TESTING AND OVULATION PREDICTION KITS, BY REGION, 2018-2026 (USD BILLION)
TABLE 28. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING AND CARRIER TESTING, BY REGION, 2018-2026 (USD BILLION)
TABLE 29. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2026 (USD BILLION)
TABLE 30. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY DOWN SYNDROME AND EDWARDS SYNDROME, BY REGION, 2018-2026 (USD BILLION)
TABLE 31. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY TORCH INFECTIONS, BY REGION, 2018-2026 (USD BILLION)
TABLE 32. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, BY REGION, 2018-2026 (USD BILLION)
TABLE 33. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TESTING, BY REGION, 2018-2026 (USD BILLION)
TABLE 34. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY HIV TESTING, BY REGION, 2018-2026 (USD BILLION)
TABLE 35. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, BY REGION, 2018-2026 (USD BILLION)
TABLE 36. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST IMAGING, BY REGION, 2018-2026 (USD BILLION)
TABLE 37. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY OB/GYN IMAGING, BY REGION, 2018-2026 (USD BILLION)
TABLE 38. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 39. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE, BY REGION, 2018-2026 (USD BILLION)
TABLE 40. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY SELF CHECK, BY REGION, 2018-2026 (USD BILLION)
TABLE 41. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 42. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC AND IMAGING CENTERS, BY REGION, 2018-2026 (USD BILLION)
TABLE 43. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2026 (USD BILLION)
TABLE 44. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2026 (USD BILLION)
TABLE 45. AMERICAS WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 46. ARGENTINA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 47. BRAZIL WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 48. CANADA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 49. MEXICO WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 50. UNITED STATES WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 51. ASIA-PACIFIC WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 52. AUSTRALIA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 53. CHINA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 54. INDIA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 55. INDONESIA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 56. JAPAN WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 57. MALAYSIA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 58. PHILIPPINES WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 59. SINGAPORE WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 60. SOUTH KOREA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 61. THAILAND WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 62. EUROPE, MIDDLE EAST & AFRICA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 63. FRANCE WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 64. GERMANY WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 65. ITALY WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 66. NETHERLANDS WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 67. QATAR WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 68. RUSSIA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 69. SAUDI ARABIA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 70. SOUTH AFRICA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 71. SPAIN WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 72. UNITED ARAB EMIRATES WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 73. UNITED KINGDOM WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 74. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET: SCORES
TABLE 75. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET: BUSINESS STRATEGY
TABLE 76. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET: PRODUCT SATISFACTION
TABLE 77. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET: RANKING
TABLE 78. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 79. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET: MERGER & ACQUISITION
TABLE 80. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 81. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 82. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET: INVESTMENT & FUNDING
TABLE 83. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 84. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • AccuBioTech Co., Ltd.
  • Alere Inc.
  • Becton, Dickinson and Company
  • Biomérieux SA
  • bioMérieux SA
  • Cardinal Health, Inc.
  • Carestream Health, Inc.
  • Chembio Diagnostic Systems, Inc.
  • Cook Medical, Inc.
  • Danaher Corporation
  • DIALAB GmbH
  • EKF Diagnostics Holdings plc
  • F. Hoffmann-La Roche Ltd.
  • FUJIFILM Holdings Corporation
  • GE Healthcare
  • Guided Therapeutics, Inc.
  • Hologic, Inc.
  • Koninklijke Philips N.V.
  • MedGyn Products, Inc.
  • NeuroLogica Corporation
  • Nova Biomedical
  • Osteometer MediTech, Inc.
  • Perkinelmer Inc.
  • Quest Diagnostics Incorporated
  • Siemens AG
  • SuperSonic Imagine
  • WerfenLife, S.A.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll